Healthcare Industry News: antibiotic
News Release - November 17, 2010
PolyMedix Appoints Steffen Helmling, Ph.D. as Vice President of Business DevelopmentRADNOR, Pa.--(Healthcare Sales & Marketing Network)-- PolyMedix, Inc. (OTC BB:PYMX.ob ), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has appointed Steffen Helmling, Ph.D. as Vice President, Business Development at PolyMedix. In this role, Dr. Helmling will be responsible for business development initiatives, including partnering and licensing activities related to PolyMedix’s pipeline of product candidates in development.
“We are pleased to have Steffen join our management team,” commented Nicholas Landekic, President and CEO of PolyMedix. “He brings an impressive background in negotiating licensing agreements, managing partnerships, and conducting market assessments. His expertise and track record of achievements will be a major asset as we advance our programs through the clinic and continue to explore opportunities for partnerships with pharmaceutical companies.”
Dr. Helmling joins PolyMedix from Noxxon Pharma, Inc., where he held positions of increasing responsibility, most recently serving as Executive Vice President, Business Development. During his tenure at Noxxon Pharma, Dr. Helmling developed and managed drug discovery partnerships with pharmaceutical companies including Pfizer, Roche, and Eli Lilly. He holds a Master’s degree in biology from Bowling Green State University and a Ph.D. in biochemistry from the Sackler School of Biomedical Sciences at Tufts University.
About PolyMedix, Inc.
PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs for the treatment of serious infectious diseases and acute cardiovascular disorders. PolyMedix uses a rational drug design approach to create non-peptide, small-molecule drug candidates. PolyMedix’s lead antibiotic compound, PMX-30063, is currently in Phase 2 clinical trials. PMX-30063 is a small-molecule that mimics the mechanism of action of human host defense proteins, a mechanism that is distinct from currently approved antibiotic drugs and is intended to make bacterial resistance unlikely to develop. PolyMedix plans to develop this compound for serious systemic Staphylococcal infections, including methicillin resistant Staphylococcus aureus (MRSA). PolyMedix’s lead heptagonist compound, PMX-60056, has completed Phase 1 testing and is being developed to reverse the anticoagulant activity of both heparin and low molecular weight heparins (LMWH). PolyMedix believes that PMX-60056 could potentially be a safer and easier to use anticoagulant reversing agent, with broader activity, than the currently approved therapy for reversing heparin and LMWH. In addition to its small molecule therapeutics, PolyMedix has polymeric formulations with the same mechanism of action as PMX-30063, PolyCides™. PolyCides are intended for use in antimicrobial biomaterials applications as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. For more information, please visit our website at www.polymedix.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause PolyMedix’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are PolyMedix’s need for, and the availability of, substantial capital in the future to fund its operations and research and development, and the fact that PolyMedix’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in PolyMedix’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.